Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

著者: Harry P. Erba, Amir T. Fathi, Ghayas C. Issa, Jessica K. Altman, Pau Montesinos, Mrinal M. Patnaik, James M. Foran, Stéphane de Botton, Maria R. Baer, Gary J. Schiller, Roland B. Walter, Marina Kremyanskaya, Kristen Pettit, Stephen A. Strickland, Blake Tomkinson, Marilyn Tabachri, Mollie Leoni, Stephen Dale, Eunice S. Wang - Blood 2022 被引用: 71